4.7 Editorial Material

Solitary bone plasmacytomas need to flow

期刊

BLOOD
卷 124, 期 8, 页码 1209-1210

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2014-06-579706

关键词

-

向作者/读者索取更多资源

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells

Stefanos I. Papadhimitriou, Evangelos Terpos, Konstantinos Liapis, Dimitrios Pavlidis, Theodoros Marinakis, Efstathios Kastritis, Meletios-Athanasios Dimopoulos, Ourania E. Tsitsilonis, Ioannis V. Kostopoulos

Summary: Plasma cell leukemia (PCL) is a rare and aggressive plasma cell dyscrasia. It can be categorized into primary and secondary types, with secondary PCL showing more abnormalities and association with del(17p13). The cytogenetic background has a significant impact on prognosis, and the level of circulating plasma cells is strongly correlated with high-risk cytogenetics, providing potential for improved prognostic stratification.

BIOMEDICINES (2022)

Article Biochemistry & Molecular Biology

Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222

Evangelos Terpos, Vangelis Karalis, Ioannis Ntanasis-Stathopoulos, Zoi Evangelakou, Maria Gavriatopoulou, Maria S. Manola, Panagiotis Malandrakis, Despoina D. Gianniou, Efstathios Kastritis, Ioannis P. Trougakos, Meletios A. Dimopoulos

Summary: This study compared the neutralizing antibody levels after vaccination with BNT162b2 mRNA vaccine and ChAdOx1 (AZD1222) viral vector vaccine at different time points. The results showed that BNT162b2 induced stronger neutralizing antibody responses compared to AZD1222, and both vaccines showed a gradual decline in antibody titers over time. Additionally, the rate of antibody elimination was higher in those vaccinated with AZD1222 compared to BNT162b2. Age, gender, body mass index, or comorbidities did not significantly impact antibody levels over time.

BIOMEDICINES (2022)

Editorial Material Biochemistry & Molecular Biology

Advances in Gynecological Cancers

Michalis Liontos, Oraianthi Fiste, Flora Zagouri, Meletios-Athanasios Dimopoulos

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Biochemistry & Molecular Biology

The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma

Maria Gkotzamanidou, Evangelos Terpos, Meletios A. A. Dimopoulos, Vassilis L. L. Souliotis

Summary: This study investigated the biological impact of the combined treatment of panobinostat and melphalan in multiple myeloma. The results showed that the combination therapy significantly reduced the efficiency of nucleotide excision repair and double-strand-break repair, increased the accumulation of DNA lesions, and increased apoptosis rate only in patients' bone marrow plasma cells.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Biochemistry & Molecular Biology

An Untargeted Metabolomics Approach on Carfilzomib-Induced Nephrotoxicity

Ioanna Barla, Panagiotis Efentakis, Sofia Lamprou, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Evangelos Terpos, Ioanna Andreadou, Nikolaos Thomaidis, Evangelos Gikas

Summary: This study investigated the nephrotoxicity caused by Cfz using metabolomics. The results showed that Cfz mainly affects the metabolome of the kidneys and urine. Fifty-four important metabolites related to renal diseases were discovered, and patterns of metabolome alterations due to Cfz were revealed.

MOLECULES (2022)

Review Oncology

Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma

Despina Fotiou, Meletios Athanasios Dimopoulos, Efstathios Kastritis

Summary: Patients with multiple myeloma have a significant risk of thrombotic complications, which require risk assessment tools and pharmacological prophylaxis. The use of newer oral anticoagulants is increasing, but data from controlled clinical trials are lacking.

CANCERS (2022)

Review Oncology

Monoclonal Gammopathy of Thrombotic Significance

Vasiliki Gkalea, Despina Fotiou, Meletios Athanasios Dimopoulos, Efstathios Kastritis

Summary: It is increasingly recognized that patients with monoclonal gammopathy (MG) who do not meet criteria for malignant disease and treatment initiation may have other manifestations that are clinically significant and could provide a rationale for treatment. These patients are at higher risk for thrombosis, including venous, arterial, and micro-thrombotic events. The challenge is to identify high-risk MG patients for thrombotic events and apply appropriate preventive measures.

CANCERS (2023)

Article Biochemistry & Molecular Biology

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma

Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Vassiliki Spiliopoulou, Efstathios Kastritis, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Maria Gavriatopoulou

Summary: This study assessed the effectiveness and tolerability of belantamab mafodotin in triple-class refractory patients with multiple myeloma. It showed promising results in some patients and had manageable toxicity.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Oncology

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer

Angeliki Andrikopoulou, Charalampos Theofanakis, Christos Markellos, Maria Kaparelou, Konstantinos Koutsoukos, Kleoniki Apostolidou, Nikolaos Thomakos, Dimitrios Haidopoulos, Alexandros Rodolakis, Meletios-Athanasios Dimopoulos, Flora Zagouri, Michalis Liontos

Summary: The optimal time interval between neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) in high-grade serous ovarian carcinoma (HGSC) is unclear. A retrospective study was conducted on HGSC patients who underwent NACT followed by IDS in a 15-year period. The study found that performing IDS within four weeks after NACT was associated with better survival outcomes. Multivariate analysis showed that a short time interval (<4 weeks) from NACT to IDS was an independent factor of both PFS and OS.

CANCERS (2023)

Article Oncology

Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial

Lisa B. Leypoldt, Maria Gavriatopoulou, Britta Besemer, Hans Salwender, Marc S. Raab, Axel Nogai, Cyrus Khandanpour, Volker Runde, Anna Jauch, Manola Zago, Peter Martus, Hartmut Goldschmidt, Carsten Bokemeyer, Meletios A. Dimopoulos, Katja C. Weisel

Summary: This study evaluated the safety and efficacy of daratumumab, bortezomib, and dexamethasone in multiple myeloma patients with severe renal function impairment. The treatment showed an overall response rate of 67% and improved renal function in patients. This study suggests that this treatment regimen could be considered in the clinical practice for multiple myeloma patients with severe renal function impairment.

CANCERS (2023)

Review Oncology

EPH/Ephrin Signaling in Normal Hematopoiesis and Hematologic Malignancies: Deciphering Their Intricate Role and Unraveling Possible New Therapeutic Targets

Ioanna E. Stergiou, Stavros P. Papadakos, Anna Karyda, Ourania E. Tsitsilonis, Meletios-Athanasios Dimopoulos, Stamatios Theocharis

Summary: The EPH/ephrin signaling axis plays a crucial role in both embryonic development and adult life, and recent studies have shown its involvement in the pathogenesis of various types of solid tumors. In normal hematopoiesis, different patterns of EPH/ephrin expression are associated with the maintenance, differentiation, and function of hematopoietic stem cells and their mature offspring. Abnormalities in the EPH/ephrin pathway have been found to contribute to the development of hematologic malignancies, with both tumor-promoting and tumor-suppressive effects. Understanding the complexity of this signaling pathway in normal and malignant hematopoiesis is essential for the development of potential therapeutic targets.

CANCERS (2023)

Review Medicine, General & Internal

Tenofovir-Induced Fanconi Syndrome Presenting with Life-Threatening Hypokalemia: Review of the Literature and Recommendations for Early Detection

Efstathia Liatsou, Ioanna Tatouli, Andreas Mpozikas, Maria-Markella Pavlou, Hariklia Gakiopoulou, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Sofoklis Kontogiannis, Meletios Athanasios Dimopoulos

Summary: Tenofovir disoproxil fumarate (TDF) is a drug used to treat patients with HIV and HBV infections, but it may cause acute renal failure and Fanconi syndrome in a few cases. The risk of renal toxicity in HBV patients appears to be low, but kidney function should still be monitored.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Biochemistry & Molecular Biology

Metabolomics Point out the Effects of Carfilzomib on Aromatic Amino Acid Biosynthesis and Degradation

Ioanna Barla, Panagiotis Efentakis, Sofia Lamprou, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Evangelos Terpos, Ioanna Andreadou, Nikolaos Thomaidis, Evangelos Gikas

Summary: The antineoplastic agent carfilzomib (Cfz) is used to treat multiple myeloma; however, it can cause cardiotoxicity and nephrotoxicity as common adverse effects. While the mechanisms of these side effects are well-established, there is limited research on the drug's metabolic alterations and their impacts.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Medicine, Research & Experimental

Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era

Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, Panagiotis Malandrakis, Evangelos Eleutherakis-Papaiakovou, Vassiliki Spiliopoulou, Rodanthi-Eleni Syrigou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Maria Roussou, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Evangelos Terpos

Summary: Tixagevimab/cilgavimab (Evusheld) appears to be beneficial for high-risk immunocompromised patients with multiple myeloma in preventing COVID-19. Administration of the drug resulted in increased neutralizing-antibody levels and a low incidence of COVID-19, with no new safety concerns emerging.

DISEASES (2023)

Article Oncology

Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study

Aristotelis Bamias, Kimon Tzannis, Roubini Zakopoulou, Minas Sakellakis, John Dimitriadis, Alkistis Papatheodoridi, Loukianos Rallidis, Panagiotis Halvatsiotis, Anna Tsiara, Maria Kaparelou, Efthymios Kostouros, Despina Barbarousi, Konstantinos Koutsoukos, Evangelos Fragiadis, Athanasios E. Dellis, Ioannis Anastasiou, Konstantinos Stravodimos, Alexandros Pinitas, Athanasios Papatsoris, Ioannis Adamakis, Ioannis Varkarakis, Charalampos Fragoulis, Stamatina Pagoni, Charis Matsouka, Andreas Skolarikos, Dionysios Mitropoulos, Konstantinos Doumas, Charalampos Deliveliotis, Constantinos Constantinides, Meletios-Athanasios Dimopoulos

Summary: This study investigated the incidence of arterial thromboembolic events (ATEs) in patients with advanced urinary tract cancer (aUTC) who received cytotoxic chemotherapy. The results showed that ATEs occurred in 4.6% of these patients, with ischemic stroke being the most common ATE. Perioperative chemotherapy, tumors other than urinary tract cancer, and pure non-transitional cell carcinoma histology were identified as independent risk factors for ATE.

CURRENT ONCOLOGY (2022)

暂无数据